MDNAF — Medicenna Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Medicenna Announces New Data Providing Preliminary Evidence Of MDNA11's Anti-Cancer Activity In Phase 1/2 Study
U.S. RESEARCH ROUNDUP-Alexandria Real Estate Equities, Beacon Roofing Supply, Snowflake
Brief: Medicenna Strengthens Intellectual Property Protection For Superkine Platform With Issuance Of U.S. Patent
Brief: Medicenna Presents Phase 1/2 Ability Study Data Highlighting Mdna11’S Favorable Clinical Profile At The 2022 Frontiers In Cancer Immunotherapy Meeting
Brief: Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation Of Anti-Cancer Immune Cells With Mdna11 In Phase 1/2 Ability Study
Medicenna rises on promising pre-clinical data for cancer therapy
Medicenna Therapeutics Corp reports results for the quarter ended in December - Earnings Summary
Brief: Medicenna Reports Third Quarter Fiscal 2022 Financial Results And Operational Highlights
Brief: Medicenna Announces Formation Of Its Scientific Advisory Board
Brief: Medicenna Publishes Peer-Reviewed Preclinical Data On MDNA11 In The Journal For Immunotherapy Of Cancer
Brief: Medicenna Announces Management Change And Appoints Experienced Development Advisory Committee
U.S. STOCKS ON THE MOVE-Allen Pharmaceuticals, Nine Energy, Core & Main
Brief: Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation Of Anti-Cancer Immune Cells With MDNA11 Treatment
Brief: Medicenna Receives Regulatory Clearance To Expand Phase 1/2 Ability Study Of MDNA11 To Canada
Brief: Medicenna Reports Q2 Fiscal 2022 Financial Results And Operational Highlights
Brief: Medicenna Announces FDA Clearance Of Ind To Expand The Phase 1/2 Ability Study Of Mdna11 To The United States
Brief: Medicenna Appoints John Sampson To Its Board Of Directors
Brief: Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study
Brief: Medicenna Reports First Quarter Fiscal 2022 Financial Results And Operational Highlights